Company Overview
| Stock Name | Dingdang Health |
|---|---|
| Stock Code | 09886 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 作為中國提供數字醫療健康到家服務的服務提供商,提供即時藥品零售、在線診療及慢病與健康管理,通過線上平台、線下智慧藥房及快藥服務運營。 |
| Listing Date | 2022-09-14 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國 北京市 東城區 燈市口大街 50號院1號樓 |
| Business Address (Hong Kong) | 香港 中環 皇后大道中99號中環中心 35樓3512單元 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.ddjkjt.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 12.00 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 6,000 |
| Par Value | To be extracted |
| Offer Period | 2022-09-01 to 2022-09-06 |
| Global Offering Shares | 33,537,000 shares |
| HK Public Offer Shares (Initial) | 3,354,000 shares (10.0%) |
| Public Offer Lots (Initial) | 6,708lots (Pool A3,354lots,Pool B3,354lots) |
| International Placing Shares (Initial) | 30,183,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,341,472,897 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 74.1% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 402,444,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 6,000 |
| 2 lots | 1,000 | HK$ 12,000 |
| 3 lots | 1,500 | HK$ 18,000 |
| 4 lots | 2,000 | HK$ 24,000 |
| 5 lots | 2,500 | HK$ 30,000 |
| 6 lots | 3,000 | HK$ 36,000 |
| 7 lots | 3,500 | HK$ 42,000 |
| 8 lots | 4,000 | HK$ 48,000 |
| 9 lots | 4,500 | HK$ 54,000 |
| 10 lots | 5,000 | HK$ 60,000 |
| 12 lots | 6,000 | HK$ 72,000 |
| 14 lots | 7,000 | HK$ 84,000 |
| 16 lots | 8,000 | HK$ 96,000 |
| 18 lots | 9,000 | HK$ 108,000 |
| 20 lots | 10,000 | HK$ 120,000 |
| 30 lots | 15,000 | HK$ 180,000 |
| 40 lots | 20,000 | HK$ 240,000 |
| 50 lots | 25,000 | HK$ 300,000 |
| 60 lots | 30,000 | HK$ 360,000 |
| 70 lots | 35,000 | HK$ 420,000 |
| 80 lots | 40,000 | HK$ 480,000 |
| 90 lots | 45,000 | HK$ 540,000 |
| 100 lots | 50,000 | HK$ 600,000 |
| 120 lots | 60,000 | HK$ 720,000 |
| 140 lots | 70,000 | HK$ 840,000 |
| 160 lots | 80,000 | HK$ 960,000 |
| 180 lots | 90,000 | HK$ 1,080,000 |
| 200 lots | 100,000 | HK$ 1,200,000 |
| 400 lots | 200,000 | HK$ 2,400,000 |
| 800 lots | 400,000 | HK$ 4,800,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,000 lots | 500,000 | HK$ 6,000,000 |
| 2,000 lots | 1,000,000 | HK$ 12,000,000 |
| 3,354 lots | 1,677,000 | HK$ 20,124,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 1.08B |
| Est. Threshold | HK$ 9.39B |
| Analysis Result | HK market cap below threshold, need +767% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 16,097,674,764 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損人民幣1,598.97百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Revenue | 1,275,589 | 2,228,563 | 3,678,690 |
| Cost of sales | -805,635 | -1,462,370 | -2,516,379 |
| Gross profit | 469,954 | 766,193 | 1,162,311 |
| Other income and gains, net | 5,145 | 16,230 | 15,905 |
| Selling and distribution expenses | -278,464 | -441,310 | -834,783 |
| Administrative expenses | -57,900 | -120,968 | -481,256 |
| Net finance costs | -5,571 | -6,061 | -17,776 |
| Share of associates and JVs | -91 | -256 | 0 |
| Profit before tax | -265,696 | -900,887 | -1,581,859 |
| Income tax expense | -8,236 | -18,793 | -17,115 |
| Profit for the year | -273,932 | -919,680 | -1,598,974 |
| Profit attributable to owners | -276,635 | -924,250 | -1,578,026 |
Balance Sheet
| Item | 2019 | 2020 | 2021 |
|---|---|---|---|
| Cash and cash equivalents | 144,691 | 260,574 | 1,552,994 |
| Trade and bills receivables | 87,932 | 187,584 | 279,591 |
| Inventories | 168,549 | 323,470 | 434,022 |
| Total current assets | 445,253 | 1,093,417 | 2,267,693 |
| Total assets | 754,177 | 1,786,146 | 2,946,159 |
| Total current liabilities | 332,224 | 601,505 | 738,929 |
| Total liabilities | 1,191,587 | 3,091,188 | 5,535,988 |
| Total equity | -437,410 | -1,305,042 | -2,589,829 |
| Equity attributable to owners | -447,062 | -1,358,415 | -2,612,247 |
Cash Flow Statement
| Item | 2018 | 2019 | 2020 | 2021-03 | 2021 | 2022-03 |
|---|---|---|---|---|---|---|
| Net cash from operating activities | -265,897 | -193,046 | -295,490 | |||
| Depreciation of PP&E | 12,962 | 16,782 | 20,879 | 5,425 | 21,650 | 5,146 |
| Depreciation of right-of-use assets | 19,561 | 35,593 | 47,742 | 15,887 | 78,404 | 19,083 |
| Amortisation of intangible assets | 590 | 5,108 | 6,257 | 8,785 | 35,232 | 8,825 |
| Purchase of PP&E | -10,540 | -20,276 | -19,595 | -3,840 | -20,466 | -5,756 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 12.0 |
|---|---|
| First Day Open | HK$ 12.34 |
| First Day Change | -91.67% |
| First Day Volume | 4346000.0 |
| First Day Turnover | 52933400.0 |
| Use of Proceeds | 1、約45.0%或約153.7百萬港元預期將用于業務擴張;
2、約15.0%或約51.2百萬港元用于優化我們的技術系統及運營平臺;
3、約10.0%或約34.2百萬港元用于提升我們的服務及業務;
4、約20.0%或約68.3百萬港元用于對我們經營的醫療產業價值鏈進行的潛在投資及收購或戰略合作;
5、約10.0%或約34.2百萬港元用于營運資金及其他一般公司用途。 |
Underwriting Syndicate
Joint Lead Managers (4)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Harvest International Premium Value (Secondary Market) Fund SPC | 78,462,000 HKD | — | 19.50% | — | 6 months | 2023-03-14 |
| 2 | Jumpcan International Co., Ltd. | 23,538,000 HKD | — | 5.85% | — | 6 months | 2023-03-14 |
| 3 | 阳光人寿保险股份有限公司 | 196,158,000 HKD | — | 48.74% | — | 6 months | 2023-03-14 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 楊文龍 | — |
| Company Secretary | 王永智、林曉波 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 控股股東集團(楊文龍先生、楊益斌先生、楊瀟先生及相關公司)緊隨全球發售完成後(假設超額配股權未獲行使)合共持有約49.21%已發行股份;其他主要股東包括招銀金融控股(深圳)有限公司(7.10%)及TPG Asia VII(6.18%)。 |
|---|




